Page last updated: 2024-10-30

lg 100268 and Experimental Mammary Neoplasms

lg 100268 has been researched along with Experimental Mammary Neoplasms in 6 studies

LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source

Research Excerpts

ExcerptRelevanceReference
"Bexarotene treatment at a dose of 250 mg/kg diet was associated with reductions in tumor multiplicity of 84% (P < 0."1.33Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas. ( Brose, HL; Gould, MN; Haag, JD; Hitt, AA; Hu, R; Kim, K; Lindstrom, MJ; Lubet, RA; Mau, B; Monson, DM; Steele, VE; Waller, JL; Watson, PA; Woditschka, S; Zheng, Y, 2006)
" We also show that it is not necessary to administer Arz and 268 continuously during tumor progression to prevent cancer in the rat model because dosing of these drugs in combination for relatively short periods, each followed by drug-free rests, is highly effective."1.32The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. ( Berchuck, A; Heyman, RA; Krajewski, S; Lamph, WW; Liby, K; Reed, JC; Rendi, MH; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR, 2004)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liby, K3
Risingsong, R4
Royce, DB3
Williams, CR4
Yore, MM1
Honda, T1
Gribble, GW1
Lamph, WW3
Vannini, N1
Sogno, I1
Albini, A1
Sporn, MB4
Mazumdar, A1
Medina, D1
Kittrell, FS1
Zhang, Y1
Hill, JL1
Edwards, DE1
Bissonnette, RP1
Brown, PH1
Suh, N3
Glasebrook, AL1
Grese, TA1
Palkowitz, AD1
Farris, MR1
Heyman, RA2
Rendi, MH1
Krajewski, S2
Reed, JC1
Berchuck, A1
Woditschka, S1
Haag, JD1
Waller, JL1
Monson, DM1
Hitt, AA1
Brose, HL1
Hu, R1
Zheng, Y1
Watson, PA1
Kim, K1
Lindstrom, MJ1
Mau, B1
Steele, VE1
Lubet, RA1
Gould, MN1
Rendi, M1
Lamph, W1
Labrie, F1
Xu, X1
Kim, H1
Brown, P1

Other Studies

6 other studies available for lg 100268 and Experimental Mammary Neoplasms

ArticleYear
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-15, Volume: 14, Issue:14

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols

2008
The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.
    Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:10

    Topics: Animals; Blotting, Western; Bone Density Conservation Agents; Female; Immunoenzyme Techniques; Mamma

2012
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

    Topics: Animals; Anticarcinogenic Agents; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Female

2002
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
    Cancer research, 2004, May-15, Volume: 64, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Mammary Neoplasm

2004
Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
    Cancer research, 2006, Jul-01, Volume: 66, Issue:13

    Topics: Animals; Anticarcinogenic Agents; Bexarotene; Body Weight; Disease Models, Animal; Female; Genes, er

2006
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19

    Topics: Animals; Cell Division; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; H

2006